What are the NICE guidelines for prescribing naloxegol?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

NICE Guidelines for Prescribing Naloxegol

Note: The evidence provided does not contain NICE (National Institute for Health and Care Excellence) guidelines specifically. However, I can provide guidance based on the available American Gastroenterological Association (AGA) guidelines and FDA labeling, which represent the highest quality evidence for naloxegol prescribing.

Primary Recommendation

Naloxegol should be prescribed for adult patients with opioid-induced constipation (OIC) who have failed first-line laxative therapy, at a dose of 25 mg once daily on an empty stomach. 1, 2

Prescribing Algorithm

Step 1: Confirm Indication

  • Patient must have chronic non-cancer pain (including chronic pain related to prior cancer or its treatment without frequent opioid dose escalation) 2
  • Patient must have documented OIC that has not responded adequately to laxatives 1
  • Consider using Bowel Function Index (mean score of ease of defecation, incomplete evacuation, and constipation severity on 0-100 scales) to objectively assess laxative failure 1

Step 2: Check Contraindications

Absolute contraindications 2:

  • Known or suspected gastrointestinal obstruction or patients at risk of recurrent obstruction
  • Concomitant use with strong CYP3A4 inhibitors (clarithromycin, ketoconazole, itraconazole)
  • Known serious or severe hypersensitivity to naloxegol

Step 3: Assess for Dose Modifications

Standard dose: 25 mg once daily 2

Reduce to 12.5 mg once daily if 2:

  • Renal impairment (creatinine clearance <60 mL/min) - start at 12.5 mg, may increase to 25 mg if tolerated
  • Concomitant moderate CYP3A4 inhibitors (diltiazem, erythromycin, verapamil) - avoid if possible; if unavoidable, use 12.5 mg
  • Patient does not tolerate 25 mg dose

Avoid use in 2:

  • Severe hepatic impairment

Step 4: Discontinue Maintenance Laxatives

  • Stop scheduled laxatives before starting naloxegol 2
  • May resume laxatives after 3 days if OIC symptoms persist 2

Step 5: Provide Administration Instructions

  • Take on empty stomach: at least 1 hour before first meal OR 2 hours after a meal 2
  • Avoid grapefruit and grapefruit juice 2
  • For patients unable to swallow tablets: may crush and give orally or via nasogastric tube 2
  • Discontinue naloxegol if opioid therapy is discontinued 2

Evidence Quality

The AGA provides a strong recommendation with moderate-quality evidence for naloxegol over no treatment in laxative-refractory OIC 1. This is based on multiple phase 3 trials showing naloxegol achieved higher response rates (risk ratio 1.43; 95% CI 1.19-1.71) compared to placebo 1.

Important Caveats

Timing Consideration

  • Patients receiving opioids for less than 4 weeks may be less responsive to naloxegol 2

Safety Monitoring

Monitor for 2:

  • Opioid withdrawal symptoms - particularly in patients with disrupted blood-brain barrier
  • Severe abdominal pain or diarrhea - discontinue if severe symptoms develop; may restart at 12.5 mg if appropriate
  • Gastrointestinal perforation - monitor for severe, persistent, or worsening abdominal pain

Common Adverse Effects (≥3%)

Abdominal pain, diarrhea, nausea, flatulence, vomiting, headache 2

Drug Interactions to Avoid

  • Strong CYP3A4 inducers (rifampin) - not recommended, as they decrease naloxegol concentrations 2
  • Other opioid antagonists - avoid concomitant use due to additive effects and increased opioid withdrawal risk 2

Comparative Context

While naldemedine has higher quality evidence (strong recommendation with high-quality evidence) 1, naloxegol remains a strong option with moderate-quality evidence and is FDA-approved since 2014 as the first PAMORA for OIC management 1. Recent comparative data suggest oral naloxegol is noninferior to subcutaneous methylnaltrexone and costs approximately $193 less per patient 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.